APA (7th ed.) Citation

Erba, H. P., Montesinos, P., Kim, H., Patkowska, E., Vrhovac, R., Žák, P., . . . Schlenk, R. F. (2023). Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. The lancet, 401(10388), . https://doi.org/10.1016/S0140-6736(23)00464-6

Chicago Style (17th ed.) Citation

Erba, Harry P., et al. "Quizartinib Plus Chemotherapy in Newly Diagnosed Patients with FLT3-internal-tandem-duplication-positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet 401, no. 10388 (2023). https://doi.org/10.1016/S0140-6736(23)00464-6.

MLA (9th ed.) Citation

Erba, Harry P., et al. "Quizartinib Plus Chemotherapy in Newly Diagnosed Patients with FLT3-internal-tandem-duplication-positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet, vol. 401, no. 10388, 2023, https://doi.org/10.1016/S0140-6736(23)00464-6.